IMWG consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

This study provides the most current information for patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. It aims to aid clinicians to ensure that patients with myeloma receive the most appropriate care in everyday clinical practice.

The study finds that patients with symptomatic disease and organ damage (for example, those who experience hypercalcemia, renal failure, anemia, or bone lesions) must be immediately treated. To assess the risk stratification of the disease and identify chromosomal abnormalities, clinicians should use the International Staging System. If a patient has another disease, frailty, or disability, then the patient must be assessed and possibly treated with reduced-dosing of therapies. Such conditions as “bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy” are the most common disabling events that require immediate supportive care.

Authors:

Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ

Click here to view article: